Evaluation of dopamine D2/3specific binding in the cerebellum for the positron emission tomography radiotracer [11C]FLB 457: Implications for measuring cortical dopamine release
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
In a recent positron emission tomography (PET) study, we demonstrated the ability to measure amphetamine‐induced dopamine (DA) release in the human cortex with the DA D 2/3 radioligand [11 C]FLB 457. As previous studies in animals have shown that a relatively high fraction of the [11 C]FLB 457 signal in the cerebellum represents specific binding to D 2/3 receptors, there was concern that the use of the cerebellum as a measure of nonspecific binding (i.e., reference region) to derive [11 C]FLB 457 binding potential (BP) (BP ND) would bias cortical DA release measurements. Thus, we evaluated the fractional contribution of specific binding to D 2/3 receptors in the human cerebellum for [11 C]FLB 457. Six healthy human subjects (5M/1F) were studied twice with [11 C]FLB 457, once at baseline and again following a single oral dose of 15 mg of aripiprazole, a D 2/3 partial agonist. [11 C]FLB 457 distribution volume (VT) was estimated using kinetic analysis in the cortical regions of interest and potential reference regions. The change in [11 C]FLB 457 VT following aripiprazole ranged from −33 to −42% in the cortical regions of interest (ROIs). The aripiprazole‐induced change in [11 C]FLB 457 VT in three potential reference regions suggests significant specific binding the cerebellum (CER, –17 ± 12%), but not pons (PON, –10 ± 10%) and centrum semiovale (CESVL, –3 ± 12%). Nevertheless, a reanalysis of the published [11 C]FLB 457 test–retest and amphetamine studies suggests that the use of the PON VT and CESVL VT as an estimate of nonspecific binding to derive [11 C]FLB 457 BP ND in DA release studies is unlikely to be successful because it leads to less reproducible outcome measures, which in turn diminishes the ability to measure DA release in the cortex. D 2/3 blocking studies with aripiprazole and [11 C]FLB 457 suggest specific binding to D 2/3 receptors in the cerebellum. These data also suggest that the contribution of specific binding to D 2/3 receptors in the cerebellum is lower than that in the cortical ROIs and that CER VT is mostly representative of nonspecific binding. Nevertheless, caution is advised when using reference tissue methods that rely solely on the cerebellum signal as an input function to quantify [11 C]FLB 457 BP ND. Synapse, 2011. © 2011 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citation
Cited by
Slifstein, M., van de Giessen, E., Van Snellenberg, J., Thompson, J. L., Narendran, R., Gil, R., Hackett, E., Girgis, R., Ojeil, N., Moore, H., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2414 · Cited by 398
Self-citationRao, N., Northoff, G., Tagore, A., Rusjan, P., Kenk, M., Wilson, A., Houle, S., Strafella, A., Remington, G., & Mizrahi, R. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby076 · Cited by 67
Tagore, A., Schifani, C., Rao, N., Tseng, H.-H., Zakzanis, K. K., Rusjan, P. M., Houle, S., & Mizrahi, R. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.06.004 · Cited by 3
Metadata
- Authors
- Narendran, R., Mason, N. S., Chen, C., Himes, M., Keating, P., May, M. A., Rabiner, E. A., Laruelle, M., Mathis, C. A., & Frankle, W. G.
- Venue
- Synapse
- Publisher
- Wiley
- Published
- 2011-04-26
- Volume
- 65
- Issue
- 10
- Pages
- 991-997
- ISSN
- 0887-4476 (ISSN-L)
- 1098-2396
- OpenAlex
- W2095870441
- Cited by
- 36
- References
- 1
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.